HeyJaredIn the Interim...
A podcast on statistical science and clinical trials.Explore the intricacies of Bayesian statistics and adaptive clinical trials.
- Indexed episodes, last 90 days
- 10
- Latest publication
- Sep 7, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 6, 2026
Latest episodes
NFL Study of CTE: The Issues (opens the original)
Read excerpt
In this episode of "In the Interim…", Dr. Scott Berry examines three recent health-research headlines through a statistician's lens: an Adventist Health Study-2 analysis claiming eggs reduce Alzheimer's risk, an Emory University trial on high-dose vitamin D and cognition (Zhao et al.), and a British Medical Journal study led by Dr. Daniel Danishvar (Harvard, Boston University) reporting that 25 to 97 percent of deceased NFL players showed evidence of chronic traumatic encephalopathy (CTE). After
Talkin' 'bout Sweet Time (opens the original)
Read excerpt
In this episode of "In the Interim...", Dr. Scott Berry dissects prevailing concepts of “clinically meaningful difference” in clinical trials focusing on progressive diseases. Through detailed examples from pancreatic cancer (Ben Sasse, Revolution Medicines), emphysema (Elevair), Alzheimer’s disease (lecanemab), and IVF, Scott challenges the adequacy of the population-mean of a continuous outcome in reflecting true patient benefit. The episode discusses inconsistent usage and interpretation of a
Mammograms: Death Threats, Hillary Clinton and Lead-Time Bias (opens the original)
Read excerpt
In this episode of "In the Interim…", Dr. Don Berry provides a detailed account of co-chairing the 1997 NIH consensus development conference on mammography for women in their 40s. His conversation with Dr. Scott Berry covers the statistical and clinical complexities of breast cancer screening, addressing lead time and length bias, trial design limitations. Don discusses the panel’s finding, based on randomized trials and meta-analysis, that the average benefit of screening women in their 40s is
REMAP-CAP Results: Oseltamivir in Critically-Ill Influenza Patients (opens the original)
Read excerpt
In this episode of "In the Interim…", Dr. Scott Berry speaks with Dr. Srinivas Murthy, Dr. Thomas Hills, and Dr. Lindsay Berry about the REMAP-CAP trial results on oseltamivir in critically ill influenza patients. The trial used a Bayesian covariate-adjusted platform design and found oseltamivir was not effective at reducing 90-day mortality with a “98% and 99% probability of harm in 90-day mortality” compared to control. Covariate adjustment addressed baseline and site variation. Subgroup analy
ICECAP: The Results (opens the original)
Read excerpt
In this episode of "In the Interim…", Dr. Scott Berry leads a comprehensive discussion of the ICECAP trial results with four Principal Investigators: Dr. Will Meurer (Professor, Emergency Medicine and Neurology, University of Michigan; consultant to Berry Consultants), Dr. Robert Silbergleit (Professor, Emergency Medicine, University of Michigan Medical School), Dr. Romer Geocadin (Professor, Neurology, Neurosurgery, and Anesthesiology and Critical Care Medicine, Johns Hopkins University School
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.